What is Equitable access at AstraZeneca?
Embedding practices into our product portfolio to drive equitable access to healthcare — including digital health, clinical trial diversity, patient centricity, investment in rare diseases, open innovation and IP-sharing arrangements.
AstraZeneca is committed to equitable access to healthcare for patients globally. Our approach includes adapting our programmes to integrate into local systems and delivering affordable medicines to patients. We work on a cross-functional basis to develop an innovative product portfolio that drives positive global health outcomes to:
- Address unmet medical needs and barriers to access
- Increase the speed and breadth of patient access
- Drive excellence in product life cycle management
- Understand the long-term impacts of scientific advances
As a science-led, patient-focused organisation, we have an obligation to play our part in addressing health inequities and eliminating discrimination from the delivery of healthcare. This includes harnessing the power of data and analytics to transform medicines development and improve patient outcomes and experience through the use of digital technology in R&D.
We are committed to ensuring that our clinical trials represent the diversity of the communities we serve, by embedding diversity and inclusion parameters into the entire clinical development life cycle. This includes a diverse geographical selection for clinical trial development, as well as early access and continued post-trial access for clinical trial participants.
We collaborate to advance scientific understanding and build local capacity for R&D, as well as consider how our products will affect the populations they intend to treat within the R&D phases through our work on product safety and environmental stewardship.
We also consider the range of ethical patient access issues that arise from biological and medical science.